Cite
HARVARD Citation
Verstovsek, S. et al. (2016). Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. Journal of hematology & oncology. 9 (1), pp. 1-12. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Verstovsek, S. et al. (2016). Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. Journal of hematology & oncology. 9 (1), pp. 1-12. [Online].